loader2
Partner With Us NRI

Glenmark Life Sciences Ltd share Price Today

Company details

850.00
871.00
555.85
906.00
6M Return 33.94%
1Y Return 40.50%
Mkt Cap.(Cr) 10,455.84
Volume 49,189
Div Yield 2.64%
OI
-
OI Chg %
-
Volume 49,189

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Glenmark Life Sciences announced FY24 & Q4FY24 results:

Financial Highlights

  • For FY24, GLS registered revenue from operations of Rs 22,832 million, a growth of 5.6% YoY. For Q4FY24, revenue from operations was at Rs 5,366 million.
  • EBITDA for FY24 was at Rs 6,863 million, a growth of 2.2% YoY and EBITDA margins for the full year were at 30.1%. For the quarter, EBITDA stood at Rs 1,446 million and EBITDA margins were at 26.9%.
  • PAT for FY24 was at Rs 4,709 million, a growth of 0.8% YoY, whereas for the quarter it stood at Rs 979 million.
  • During FY24, company generated strong free cash flow of Rs 2,845 million leading to Cash and Cash Equivalents of Rs 3,014 million as of 31 March 2024.

Commenting on the company’s performance Dr. Yasir Rawjee, MD & CEO, Glenmark Life Sciences said, “FY24 was a milestone year for Glenmark Life Sciences, marked by the successful acquisition by Nirma Limited. With Nirma's commitment and strategic vision, we are poised for accelerated growth and market positioning.

We concluded the financial year on a positive note with revenue growth of 5.6% on full year basis, driven by regulated markets in external business.

Our commitment to high-quality, innovative solutions and scalability will fuel sustainable long-term growth. These, coupled with a strong order book and demand visibility will ensure steady growth in FY25 and beyond.”

Tushar Mistry, CFO, Glenmark Life Sciences Limited said, “Despite global uncertainties and our integration efforts with Nirma Limited, we achieved a revenue growth of 5.6% in FY24. Our annualized margins continue to be in the range of ~30% despite one-time costs such as bonuses and transaction expenses.

Our strong free cash flow generation in FY24 has bolstered our financial standing, enabling continued growth while maintaining a debt-free balance sheet.”

Result PDF

View Other Company Results

Glenmark Life Sciences Ltd shares SWOT Analysis

Strengths (7)

  • Strong Momentum: Price above short, medium and long term moving averages
  • Rising Net Cash Flow and Cash from Operating activity
  • Company with No Debt

Weakness (3)

  • Degrowth in Quarterly Revenue and Profit in Recent Results(YoY)
  • Declining Revenue every quarter for the past 2 quarters
  • Fall in Quarterly Revenue and Net Profit (YoY)

Opportunity (1)

  • RSI indicating price strength

Threats (1)

  • Increasing Trend in Non-Core Income

Resistance and support

R1 866.2
R2 879.1
R3 887.2
Pivot

858.12

S1 845.2
S2 837.1
S3 824.2
EMA SMA
845.4
828.3
801.2
742.8
841.5
827.0
822.9
733.7
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
SOCIETE GENERALE Block Purchase 2024-01-25 799.55 151173 BSE
BNP PARIBAS ARBITRAGE Block Sell 2024-01-25 799.55 151173 BSE
POLAR CAPITAL FUNDS PLC-HEALTHCARE OPPORTUNITIES FUND Bulk Purchase 2021-08-09 732.55 836000 NSE
Name Category Shares
NIRMA LIMITED PROMOTER 75%
GLENMARK PHARMACEUTICALS LIMITED PROMOTER 7.84%

OUR RESEARCH VIEW

Investment recommendation
GLS v2- Redefining growth under the new ownership …
Call Date
29 Apr 2024
Entry Price 806.00
Target Price 1,040.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Glenmark Life Sciences Ltd Stocks COMPARISON

Financials( in Cr) Glenmark Life Sciences Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Divis Laboratories Ltd Zydus Lifesciences Ltd
Price 853.35 1,516.00 1,564.75 4,588.60 1,109.55
% Change -0.55 0.34 1.31 -0.11 1.75
Mcap Cr 10,455.84 363,739.19 126,332.75 121,813.11 111,646.69
Revenue TTM Cr 2,161.22 43,885.68 15,790.60 7,767.51 17,237.40
Net Profit TTM Cr 466.96 8,560.84 2,513.47 1,823.38 1,997.30
PE TTM 22.17 36.34 29.68 76.10 28.94
1 Year Return 40.50 53.43 59.42 31.57 114.34
ROCE 29.86 16.79 14.76 19.30 16.25
ROE 22.28 16.46 10.66 14.89 14.05
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 2,138.21 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 33,119.99 -408.46
LAST 3M 113,155.52 -36,230.77
LAST 6M 183,603.09 -15,050.11
LAST 12M 290,144.87 98,834.05

Glenmark Life Sciences Ltd Information

Stock PE (TTM)
22.17
Promoter Holding
82.85%
Book Value
190.3517
ROCE
29.86%
ROE
22.28%
Description
  • The company was incorporated as `Zorg Laboratories Private Limited`, a private limited company under the Companies Act, 1956 on 23 June 2011 at Pune and was granted the certificate of incorporation by the Registrar of Companies, Maharashtra at Pune ("RoC"). Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited pursuant to the Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to `Glenmark Life Sciences Private Limited` pursuant to a special resolution passed by the shareholders of the Company on 25 July 2018 and a fresh certificate of incorporation dated 10 August 2018 was issued by the RoC. A shareholders` resolution was passed on 13 August 2018 to convert the Company from a private limited company to a public limited company and a fresh certificate of incorporation dated 28 August 2018 was issued by the RoC. The Company is a wholly owned Subsidiary of Glenmark Pharmaceuticals Limited. The Company acquired API division of Glenmark Pharmaceuticals Limited (the parent company) on 01 January 2019. The company is primarily engaged in the business of development,manufacture and marketing of Active Pharmaceutical Ingredients(APIs). The company`s R&D facilities are located at Mahape,Ankleshwar and Dahej and manufacturing facilities are located at Ankleshwar,Dahej,Mohol and Kurkumbh. During the year 2018-19, the company allotted 4,50,090 Equity Shares of Rs. 10/- each on the conversion of loan given to Director. During the year, 15,00,000 equity shares of the face value of Rs. 10 each fully paid-up issued to Glenmark Pharmaceuticals Limited (Parent Company) pursuant to the Preferential Allotment. Subsequent to the quarter ended 30 June 2021, the company has completed the IPO of 21,022,222 equity shares comprising a fresh issue of 14,722,222 equity shares and offer for sale of 6,300,000 equity shares of face value of Rs 2 each at premium of Rs 718 per share aggregating to Rs 15,136 million. Pursuant to the IPO, the equity shares of the Company are listed on BSE Limited and National Stock Exchange of India Limited with effect from 06 August 2021. The Gross Debt comprising of Outstanding Purchase Consideration payable to the Parent Company was Rs 8,008.3 million as on 09 July 2021.The Company has repaid the whole of this remaining outstanding purchase consideration from the proceeds of the Fresh Issue pursuant to the IPO.

Registered Address

Plot No. 170-172 Chandramouli, Industrial Est.Mohol Bazarpeth, Solapur, Maharashtra, 413213

Tel : 91-2189-234456/234246
Email : complianceofficer:glenmarklifesciences.com
Website : http://www.glenmarklifesciences.com
Registrar

KFin Techologies Ltd

AGM Date (Month) : Sep
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 543322
NSE Code : GLS
Book Closure Date (Month) : Sep
BSE Group : A
ISIN : INE03Q201024

FAQ’s on Glenmark Life Sciences Ltd Shares

You can buy Glenmark Life Sciences Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Glenmark Life Sciences Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Jun 14, 2024 03:53 PM the closing price of Glenmark Life Sciences Ltd was Rs.853.35.

The latest PE ratio of Glenmark Life Sciences Ltd as of Jun 14, 2024 03:53 PM is 22.17

The latest PB ratio of Glenmark Life Sciences Ltd as of Jun 14, 2024 03:53 PM is 0.22

The 52-week high of Glenmark Life Sciences Ltd share price is Rs. 906.00 while the 52-week low is Rs. 555.85

According to analyst recommendations, Glenmark Life Sciences Ltd Share has a "Buy" rating for the long term.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Jun 14, 2024 03:53 PM, the market cap of Glenmark Life Sciences Ltd stood at Rs. 10,455.84.

Download App

Download Our App

Play Store App Store
market app